The survey of 726 Americans reveals strong bipartisan support for healthcare reform measures, particularly patent system changes that could increase market competition and reduce drug prices.
reports.i-mak.org/drug-pricing...

Watch the full exchange here👇

Swipe to see how readers are reacting 👇

As Rebecca Robbins of the Times details, Amgen—the company that markets Enbrel—has relied on legal loopholes and anti-competitive patenting schemes to extend its monopoly over the drug and block American patients from accessing cheaper biosimilar versions.

Enbrel is a biologic drug used to treat several conditions, including rheumatoid arthritis and plaque psoriasis. The list price was about $11,000 for an annual treatment when it first launched nearly 30 years ago. Today, it’s $106,000 and it has no competition.

Also, don’t forget to RSVP to our webinar tomorrow morning, where we’ll review new survey results that break down the growing bipartisan support for patent system reform! We’ll hear from @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, and @emilypisacreta.bsky.social.
www.i-mak.org/survey/

The scheme, known as a “product hop”, will effectively allow Merck to restart its patent monopoly on Keytruda just as the 20-year monopoly on the IV version comes to an end. This is blatant abuse of the U.S. patent system.
www.nytimes.com/2025/09/19/h...